A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: MK-1045
BIOLOGICAL: Blinatumomab
DRUG: Acetaminophen
DRUG: Diphenhydramine
DRUG: Dexamethasone
DRUG: Tocilizumab
DRUG: Siltuximab
DRUG: Avtozma
DRUG: Tyenne

Sponsor

Merck Sharp & Dohme LLC